Clinical Trials

Lymphoma, T-Cell, Peripheral

NCT06083701 2023-10-16

Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study

32 enrolled

Lymphoma, T-Cell, Peripheral

NCT05979792 2023-08-21

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

35 enrolled

Lymphoma, T-Cell, Peripheral

NCT05976997 2023-08-04

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

36 enrolled

Lymphoma, T-Cell, Peripheral

NCT04480099 2023-06-13

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

96 enrolled

Lymphoma, T-Cell, Peripheral

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

116 enrolled

Lymphoma, T-Cell, Peripheral

NCT05527275 2022-09-02

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

78 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05495100 2022-08-10

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

45 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05458180 2022-07-14

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

18 enrolled

Lymphoma, T-Cell, Peripheral

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

60 enrolled

Lymphoma, T-Cell, Peripheral

NCT04480125 2022-04-20

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

28 enrolled

Lymphoma, T-Cell, Peripheral

NCT03629873 2022-01-03

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

69 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell

NCT05006664 2021-09-01

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

33 enrolled

Lymphoma, T-Cell, Peripheral

NCT04880746 2021-05-11

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Phase 3 Unknown

266 enrolled

Lymphoma, T-Cell, Peripheral

NCT04052659 2021-03-09

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT03502629 2021-03-03

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

86 enrolled

Lymphoma, T-Cell, Peripheral

NCT04767308 2021-02-23

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

LymphoidOther hematologic neoplasm

18 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT04108325 2021-01-28

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

58 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04480788 2021-01-06

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

9 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT04696705 2021-01-06

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

10 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT04489264 2020-12-04

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Unknown

60 enrolled

Lymphoma, T-Cell, Peripheral

NCT04615468 2020-11-04

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

78 enrolled

Lymphoma, T-Cell, Peripheral

NCT03921879 2020-10-23

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

50 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02445404 2020-10-22

Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

134 enrolled

Lymphoma, T-Cell, Peripheral

NCT04457830 2020-10-22

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

105 enrolled

Lymphoma, T-Cell, Peripheral

NCT04470141 2020-07-14

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

130 enrolled

Lymphoma, T-Cell, Peripheral

NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Phase 4 Unknown

100 enrolled

Lymphoma, T-Cell, Peripheral

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

44 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04028440 2019-09-26

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

LymphoidOther hematologic neoplasm

6 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral

NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

54 enrolled

Lymphoma, T-Cell, Peripheral

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies